123 related articles for article (PubMed ID: 25879373)
1. Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.
Marusic C; Novelli F; Salzano AM; Scaloni A; Benvenuto E; Pioli C; Donini M
Plant Biotechnol J; 2016 Jan; 14(1):240-51. PubMed ID: 25879373
[TBL] [Abstract][Full Text] [Related]
2. N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.
Marusic C; Pioli C; Stelter S; Novelli F; Lonoce C; Morrocchi E; Benvenuto E; Salzano AM; Scaloni A; Donini M
Biotechnol Bioeng; 2018 Mar; 115(3):565-576. PubMed ID: 29178403
[TBL] [Abstract][Full Text] [Related]
3. Optimisation of the purification process of a tumour-targeting antibody produced in N. benthamiana using vacuum-agroinfiltration.
Lombardi R; Villani ME; Di Carli M; Brunetti P; Benvenuto E; Donini M
Transgenic Res; 2010 Dec; 19(6):1083-97. PubMed ID: 20229286
[TBL] [Abstract][Full Text] [Related]
4. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the Secretion of a Glyco-Engineered Anti-CD20 scFv-Fc Antibody in Hairy Root Cultures.
Lonoce C; Marusic C; Morrocchi E; Salzano AM; Scaloni A; Novelli F; Pioli C; Feeney M; Frigerio L; Donini M
Biotechnol J; 2019 Mar; 14(3):e1800081. PubMed ID: 29975457
[TBL] [Abstract][Full Text] [Related]
6. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
7. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
8. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
9. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
Demidem A; Lam T; Alas S; Hariharan K; Hanna N; Bonavida B
Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
[TBL] [Abstract][Full Text] [Related]
10. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis.
Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344
[TBL] [Abstract][Full Text] [Related]
11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
[TBL] [Abstract][Full Text] [Related]
14. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
16. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CD20 Binding Affinities of Rituximab Produced in Nicotiana benthamiana Leaves and Arabidopsis thaliana Callus.
Kang CE; Lee S; Seo DH; Heo W; Kwon SH; Kim J; Lee J; Ko BJ; Koiwa H; Kim WT; Kim JY
Mol Biotechnol; 2021 Nov; 63(11):1016-1029. PubMed ID: 34185248
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
19. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
[TBL] [Abstract][Full Text] [Related]
20. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
